Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system

International Journal of Cancer

Volumn 125, Issue 8, 2009, Pages 1975-1984

  Fukazawa, Takuya ^a   Maeda, Yutaka ^b   Matsuoka, Junji ^a   Tanaka, Noriaki ^a   Tanaka, Hirotoshi ^c   Durbin, Mary L ^d   Naomoto, Yoshio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; Glucocorticoid; Lung cancer; TTS

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; HUMAN SURFACTANT PROTEIN A1; PROTEIN BID; SURFACTANT PROTEIN A; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR TTF1; UNCLASSIFIED DRUG; CASPASE; CYTOCHROME C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER STEM CELL; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SPECIFICITY; XENOGRAFT; ADENOCARCINOMA; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CLONOGENIC ASSAY; DRUG SCREENING; FIBROBLAST; GENETICS; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CISPLATIN; COLONY-FORMING UNITS ASSAY; CYTOCHROMES C; DEXAMETHASONE; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349242065     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24584     Document Type: Article

References (69)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002;20:1344-1352 (Pubitemid 34177441)
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The. TAX 320 Non- Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362 (Pubitemid 30415821)
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98 (Pubitemid 34438899)
5. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-1907
6. Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 2007;25:4146-4152 (Pubitemid 47492959)
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2007; 7:285-301. (Pubitemid 46733081)
8. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M. Randomized study of adjuvant chemotherapy for completely resected stage I. II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461 (Pubitemid 37279330)
9. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65
10. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 (Pubitemid 38637993)
11. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007;117:2740-2750 (Pubitemid 47529602)
12. Check E. Second cancer case halts gene-therapy trials. Nature 2003;421:305. (Pubitemid 36157908)
13. Zoltick PW, Wilson JM. Regulated gene expression in gene therapy. Ann N Y Acad Sci 2001;953:53-63.
14. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005;12:189-211. (Pubitemid 41025089)
15. Tietge UJ, Kozarsky KF, Donahee MH, Rader DJ. A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver. J Gene Med 2003;5:567-575
16. Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F, Jr, Wilson JM, Gilman M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 1999;96:8657-8662 (Pubitemid 29354847)
17. Sipo I, Wang X, Hurtado Pico A, Suckau L, Weger S, Poller W, Fechner H. Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo. Gene Ther 2006;13:173-186 (Pubitemid 43039909)
18. Chiche JD, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD, Jr, Filippov G, Janssens SP, Rosenzweig A, Bloch KD. Adenovirus- mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 1998;273:34263-34271 (Pubitemid 129758369)
19. Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB. Development of a cancer-targeted tissue-specific promoter system. Cancer Res 2004;64:363-369 (Pubitemid 38114119)
20. Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996;44:673-678
21. Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korfhagen TR. Lung cell-specific expression of the murine surfactant protein A (SPA) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem 1995;270:6531-6536
22. Fukazawa T, Maeda Y, Durbin ML, Nakai T, Matsuoka J, Tanaka H, Naomoto Y, Tanaka N. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther 2007;6:244-252 (Pubitemid 46206688)
23. Hoover RR, Thomas KH, Floros J. Glucocorticoid inhibition of human SP-A1 promoter activity in NCI-H441 cells. Biochem J 1999;340 (Part 1):69-76. (Pubitemid 29251092)
24. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10:2859-2869 (Pubitemid 26394246)
25. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument- Bromage H, Tempst P, Korsmeyer SJ. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156-1163 (Pubitemid 129535271)
26. Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 1996;271:7440-7444 (Pubitemid 26107015)
27. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000;14:2060-2071 (Pubitemid 30637355)
28. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J, Smith E, Verdine GL, Korsmeyer SJ. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006;24:199-210. (Pubitemid 44557124)
29. Fukazawa T, Walter B, Owen-Schaub LB. Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem 2003;278:25428-25434 (Pubitemid 36835293)
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-2514 (Pubitemid 28145972)
31. Jacobsen MD, Weil M, Raff MC. Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. J Cell Biol 1996;133:1041-1051 (Pubitemid 26172509)
32. Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res 2006;66:10274-10280 (Pubitemid 44799744)
33. Jones KR, Gewirtz DA, Yannone SM, Zhou S, Schatz DG, Valerie K, Povirk LF. Radiosensitization of MDA-MB-231 breast tumor cells by adenovirus-mediated overexpression of a fragment of the XRCC4 protein. Mol Cancer Ther 2005;4:1541-1547 (Pubitemid 41556436)
34. Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000;6:1016-1023 (Pubitemid 30159362)
35. Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006;106:1260-1268 (Pubitemid 43363902)
36. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917-3921
37. Montesinos MC, Desai A, Cronstein BN. Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther 2006;54:2632-2642
38. Yao X, Yoshioka Y, Eto Y, Morishige T, Okada Y, Mizuguchi H, Mukai Y, Okada N, Nakagawa S. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun 2007;362:419-424 (Pubitemid 47332425)
39. Doloff JC, Waxman DJ, Jounaidi Y. hTERT-promoter driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther 2008 Sep 4. [Epub ahead or print].
40. Davis JJ, Wang L, Dong F, Zhang L, Guo W, Teraishi F, Xu K, Ji L, Fang B. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther 2006;13:720-723 (Pubitemid 44264475)
41. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 2005;12:1608-1617 (Pubitemid 41670351)
42. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147
43. Youssef N, Paradis V, Ferlicot S, Bedossa P. In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis. J Pathol 2001;194:459-465
44. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-574
45. Kotoula V, Hytiroglou P, Pyrpasopoulou A, Saxena R, Thung SN, Papadimitriou CS. Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver 2002;22:57-69. (Pubitemid 34552526)
46. Golubovskaya VM, Filatov LV, Behe CI, Presnell SC, Hooth MJ, Smith GJ, Kaufmann WK. Telomere shortening, telomerase expression, and chromosome instability in rat hepatic epithelial stem-like cells. Mol Carcinog 1999;24:209-217
47. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002;69:188-197
48. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501. (Pubitemid 28391865)
49. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 (Pubitemid 38720929)
50. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17. (Pubitemid 40412734)
51. Ramdas J, Liu W, Harmon JM. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res 1999;59:1378-1385 (Pubitemid 29136273)
52. Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lugering N. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004;172:5103-5109 (Pubitemid 38456439)
53. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003;63:3112-3120 (Pubitemid 36735861)
54. Chang TC, Hung MW, Jiang SY, Chu JT, Chu LL, Tsai LC. Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett 1997;415:11-15
55. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003;9:93-101. (Pubitemid 36109720)
56. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9:553-566 (Pubitemid 34734419)
57. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J, Haynes H, Wadler S. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003;9:693-702. (Pubitemid 36182602)
58. Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008;26:4166-4171
59. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 and 22 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-1101 (Pubitemid 24087162)
60. Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000;23:79-85.
61. Jung K, Alekseev KP, Zhang X, Cheon DS, Vlasova AN, Saif LJ. Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus. J Virol 2007;81:13681-13693 (Pubitemid 350247861)
62. Zsengeller ZK, Wert SE, Hull WM, Hu X, Yei S, Trapnell BC, Whitsett JA. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995;6:457-467
63. Huang Y, Simons SS, Jr. Functional analysis of R651 mutations in the putative helix 6 of rat glucocorticoid receptors. Mol Cell Endocrinol 1999;158:117-130
64. Ramos RA, Meilandt WJ, Wang EC, Firestone GL. Dysfunctional glucocorticoid receptor with a single point mutation ablates the CCAAT/enhancer binding protein-dependent growth suppression response in a steroid-resistant rat hepatoma cell variant. FASEB J 1999;13:169-180
65. Yoshikawa N, Makino Y, Okamoto K, Morimoto C, Makino I, Tanaka H. Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor. J Biol Chem 2002;277:5529-5540 (Pubitemid 34968604)
66. Roach SL, Higuchi RI, Adams ME, Liu Y, Karanewsky DS, Marschke KB, Mais DE, Miner JN, Zhi L. Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines. Bioorg Med Chem Lett 2008;18:3504-3508
67. Stoff-Khalili MA, Rivera AA, Stoff A, Michael Mathis J, Rocconi RP, Matthews QL, Numnum MT, Herrmann I, Dall P, Eckhoff DE, Douglas JT, Siegal GP, et al. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Int J Cancer 2007;120:935-941 (Pubitemid 46175417)
68. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 2004;64:5753-5759 (Pubitemid 39095574)
69. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006;441:239-243